simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    New P1 trial:  Drug-Drug Interaction (DDI) Study for TPN171H (clinicaltrials.gov) -  Oct 19, 2023   
    P1,  N=24, Completed, 
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Trial completion:  Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. (clinicaltrials.gov) -  Mar 7, 2023   
    P3,  N=765, Completed, 
    Recruiting --> Completed Recruiting --> Completed
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Trial completion, Trial completion date, Trial primary completion date:  Effect of TPN171H on Spermatogenesis (clinicaltrials.gov) -  Feb 21, 2023   
    P1,  N=18, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Apr 2023 --> Dec 2022 | Trial primary completion date: Apr 2023 --> Dec 2022
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Enrollment open:  Effect of TPN171H on Spermatogenesis (clinicaltrials.gov) -  Dec 7, 2022   
    P1,  N=18, Recruiting, 
    Recruiting --> Completed | N=56 --> 16 | Trial completion date: Dec 2023 --> Oct 2022 Not yet recruiting --> Recruiting
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    New P1 trial:  Effect of TPN171H on Spermatogenesis (clinicaltrials.gov) -  Oct 19, 2022   
    P1,  N=18, Not yet recruiting, 
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Trial completion, Trial completion date:  Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Jul 1, 2022   
    P2,  N=60, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2022
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Preclinical, Journal:  TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats. (Pubmed Central) -  Jun 10, 2022   
    The results suggested that TPN171H significantly reduced RVSP and RVHI, and reversed pulmonary vascular remodeling in rats with both models. Furthermore, in in vivo and in vitro research, our data suggested that TPN171H remarkably suppressed cathepsin B-mediated NLRP3 inflammasome activation, which may contribute to its therapeutical function for PH.
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Trial completion:  A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male Subjects (clinicaltrials.gov) -  May 23, 2022   
    P1,  N=19, Completed, 
    Furthermore, in in vivo and in vitro research, our data suggested that TPN171H remarkably suppressed cathepsin B-mediated NLRP3 inflammasome activation, which may contribute to its therapeutical function for PH. Recruiting --> Completed
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Enrollment open:  Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. (clinicaltrials.gov) -  Jan 20, 2022   
    P3,  N=740, Recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2022 --> Feb 2022 Not yet recruiting --> Recruiting
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Trial completion, Trial primary completion date:  Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction (clinicaltrials.gov) -  Jan 14, 2022   
    P2,  N=255, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Apr 2021 --> Jul 2021
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Trial completion date, Trial primary completion date:  Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Oct 29, 2021   
    P2,  N=60, Recruiting, 
    Based on the half-life, food effect, and safety profile of TPN171H, we recommend a once-daily, post-meal administration of TPN171H in subsequent clinical studies in healthy subjects and patients with PAH. Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jul 2022
  • ||||||||||  simmerafil (TPN171H) / Shanghai Inst. of Materia Medica, Vigonvita Life Sci, Topharman
    Trial completion:  Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects (clinicaltrials.gov) -  Feb 25, 2021   
    P1,  N=6, Completed, 
    Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jul 2022 Recruiting --> Completed